| |
 |
P ROGRAM
O N THE
P HARMACEUTICAL
I NDUSTRY
MIT Sloan School of Management
Cambridge, Massachusetts |
|
PharmaGenomics
Journal's
Pharmacogenomics is the study of how an
individual's genetic inheritance affects the body's response to drugs.
The term comes from the words pharmacology and genomics and is thus the
intersection of pharmaceuticals and genetics. Pharmacogenomics
holds the promise that drugs might one day be tailor-made for
individuals and adapted to each person's own genetic makeup.
Environment, diet, age, lifestyle, and state of health all can influence
a person's response to medicines, but understanding an individual's
genetic makeup is thought to be the key to creating personalized drugs
with greater efficacy and safety. Pharmacogenomics combines
traditional pharmaceutical sciences such as biochemistry with annotated
knowledge of genes, proteins, and single nucleotide polymorphisms.
|
Medical
Imaging in Drug Discovery, Part II
|
|
April
27, 2004
By: Anthony J.
Sinskey , Stan N. Finkelstein , Scott M. Cooper
Molecular
imaging is beginning to be applied to pre-clinical drug development
efforts, and a number of new companies are poised to serve this
market, touting their molecular imaging technologies as specifically
aiding drug development.
|
|
|
|
Industry
Watch: Medical Imaging in Drug Discovery, Part I
|
|
March
1, 2004
By: Anthony J.
Sinskey , Stan N. Finkelstein , Scott M. Cooper
While
economic, scientific and regulatory questions still need to be
answered, imaging technologies have the potential to increase
efficiencies in many areas of drug research. This first of a
three-part series examines initial applications in clinical trials
and industry's growing interest in monitoring biomarkers throughout
discovery and development.
|
|
|
|
The
Question of Compliance
|
|
January
1, 2004
By: Anthony J.
Sinskey , Stan N. Finkelstein , Scott M. Cooper
The
full potential of personalized medicine cannot be realized if
patients don't follow their treatment regimens. The authors
address this tissue, using diabetes as an example, and discuss new
clinical monitoring and feedback systems that could complement the
industy's drug development efforts.
|
|
|
|
See
You in December?
|
|
October
1, 2003
By:
Anthony J. Sinskey , Stan N. Finkelstein , Scott M. Cooper
A
symposium was
held this winter at the Massachusetts Institute of Technology that
provides a comprehensive focus on the science and technology,
clinical medicine and economic and policy implications of
pharmacogenomics.
|
|
|
|
Getting
Personal with Pain
|
|
July
1, 2003
By: Anthony J.
Sinskey , Stan N. Finkelstein , Scott M. Cooper
Pain
research seems to be ideal for the application of pharmacogenomics,
but pharmaceutical companies have invested little research in the
area. The authors discuss opportunities and approaches in the
pain management market.
|
|
|
|
A
Public/Private Partnership for Dual-Use Antibiotics
|
|
March
1, 2003
By:
Anthony J. Sinskey , Stan N. Finkelstein , Scott M. Cooper
Pharmacogenomics
offers potential new approaches to defend against both bacterial
resistance and bioterrorism, but the pursuit of new antibiotic
medications is not particularly attractive from a business
standpoint. A public/private partnership could provide the
structure for the R&D effort.
|
|
|
|
Getting
to Rational Drug Design — at Last
|
|
November
1, 2002
By: Anthony J.
Sinskey , Stan N. Finkelstein , Scott M. Cooper
The
industry now has the research tools to pursue rational drug design
successfully, but a new hurdle is being raised: finding a way to
generate data and manage our knowledge of disease that maximizes the
value of that knowledge.
|
|
|
|
The
Coming Paradigm Shift in Pharmaceuticals
|
|
September
1, 2002
By: Anthony J.
Sinskey , Stan N. Finkelstein , Scott M. Cooper
Pharmacogenomics
holds the promise of more effective and better-tolerated therapies,
which, in turn, mean more efficient use of healthcare
resources. But there are many hurdles on the way to the
pharmacy of the future.
|
|
|
|
The
Promise of Protein Microarrays
|
|
July
1, 2002
By:
Anthony J. Sinskey , Stan N. Finkelstein , Scott M. Cooper
Despite
some formidable technical challenges, protein microarray and other
biochip technologies are among the most important tools for the
analysis of cell physiology as a set of linked networks.
|
|
|
|
Integrating
the Science and Technology Revolutions
|
|
May
1, 2002
By: Anthony J. Sinskey , Stan N.
Finkelstein , Scott M. Cooper
There's
no question that technology influences drug development, and that
innovation is one of the driving forces behind improved health
worldwide. How will new science and technology change
healthcare? What does the future hold for the pharmaceutical
industry?
|
For
more journal articles:
|
|
To
read articles on this site requires Adobe Acrobat®
Reader.
Click here for your free copy... PDF
Reader |
|
|
